Narcolepsy Market Research Report, By Type (Type 1, Type 2 Narcolepsy) Diagnosis (Poysomnogram, Multiple Sleep Latency Test) Treatment (Stimulants, Antidepressants, Sodium Oxybate) End Users (Hospitals, Retail Pharmacies) – Global Forecast Till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Narcolepsy Market, by Type

6.1 Introduction

6.2 Type 1 Narcolepsy

Market Estimates & Forecast, 2020 – 2027

6.3 Type 2 Narcolepsy

Market Estimates & Forecast, 2020 – 2027

6.4 Others

Chapter 7. Global Narcolepsy Market, by Diagnosis

7.1 Introduction

7.2 Polysomnogram

Market Estimates & Forecast, 2020 – 2027

7.3 Multiple Sleep Latency Test

Market Estimates & Forecast, 2020 – 2027

7.4 Others

Chapter 8. Global Narcolepsy Market, by Treatment

8.1 Introduction

8.2 Stimulants

Market Estimates & Forecast, 2020 – 2027

8.2.1 Modafinil

8.2.2 Armodafinil

8.2.3 Others

8.3 Antidepressants

Market Estimates & Forecast, 2020 – 2027

8.3.1 Tricyclics

Market Estimates & Forecast, 2020 – 2027

8.3.1.1 Imipramine

8.3.1.2 Desipramine

8.3.1.3 Clomipramine

8.3.1.4 Others

8.3.2 Selective Serotonin and Noradrenergic Reuptake Inhibitors

Market Estimates & Forecast, 2020 – 2027

8.3.2.1 Venlafaxine

8.3.2.2 Fluoxetine

8.3.2.3 Others

8.4 Sodium Oxybate

Market Estimates & Forecast, 2020 – 2027

8.5 Others

Chapter 9. Global Narcolepsy Market, by End User

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, 2020 – 2027

9.3 Clinics

Market Estimates & Forecast, 2020 – 2027

9.4 Retail Pharmacies

Market Estimates & Forecast, 2020 – 2027

9.5 Others

Chapter 10. Global Narcolepsy Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Jazz Pharmaceuticals plc

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 BIOPROJET

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Arena Pharmaceuticals, Inc.

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Graymark Healthcare, Inc.

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Mylan N.V.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Teva Pharmaceutical Industries Ltd.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Novartis AG

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Shire

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Shionogi Inc.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Ligand Pharmaceuticals, Inc.

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Narcolepsy Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Narcolepsy Industry Synopsis, 2020 – 2027

Table 2 Global Narcolepsy Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Narcolepsy Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Narcolepsy Market by End User, 2020 – 2027, (USD Million

Table 8 North America Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 9 North America Narcolepsy by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Narcolepsy by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Narcolepsy by End User, 2020 – 2027, (USD Million)

Table 12 U.S. Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 13 U.S. Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 U.S. Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 15 U.S. Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 16 Canada Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 17 Canada Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 20 South America Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 21 South America Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 24 Europe Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 25 Europe Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 28 Western Europe Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 29 Western Europe Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Narcolepsy Market by End User, 2020 – 2027, (USD Million)

Table 40 The Middle East & Africa Narcolepsy Market by Type, 2020 – 2027, (USD Million)

Table 41 The Middle East & Africa Narcolepsy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 The Middle East & Africa Narcolepsy Market by Treatment, 2020 – 2027, (USD Million)

Table 43 The Middle East & Africa Narcolepsy Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Narcolepsy Market

Figure 3 Market Dynamics for Global Narcolepsy Market

Figure 4 Global Narcolepsy Market Share, by Type 2020

Figure 5 Global Narcolepsy Market Share, by Diagnosis 2020

Figure 6 Global Narcolepsy Market Share, by Treatment, 2020

Figure 7 Global Narcolepsy Market Share, by End User, 2020

Figure 8 Global Narcolepsy Market Share, by Region, 2020

Figure 9 North America Narcolepsy Market Share, by Country, 2020

Figure 10 Europe Narcolepsy Market Share, by Country, 2020

Figure 11 Asia Pacific Narcolepsy Market Share, by Country, 2020

Figure 12 The Middle East & Africa Narcolepsy Market Share, by Country, 2020

Figure 13 Global Narcolepsy Market: Company Share Analysis, 2020 (%)

Figure 14 Jazz Pharmaceuticals plc.: Key Financials

Figure 15 Jazz Pharmaceuticals plc.: Segmental Revenue

Figure 16 Jazz Pharmaceuticals plc.: Geographical Revenue

Figure 17 BIOPROJET: Key Financials

Figure 18 BIOPROJET: Segmental Revenue

Figure 19 BIOPROJET: Geographical Revenue

Figure 20 Arena Pharmaceuticals, Inc.: Key Financials

Figure 21 Arena Pharmaceuticals, Inc.: Segmental Revenue

Figure 22 Arena Pharmaceuticals, Inc.: Geographical Revenue

Figure 23 Graymark Healthcare, Inc.: Key Financials

Figure 24 Graymark Healthcare, Inc.: Segmental Revenue

Figure 25 Graymark Healthcare, Inc.: Geographical Revenue

Figure 26 Mylan N.V.: Key Financials

Figure 27 Mylan N.V. : Segmental Revenue

Figure 28 Mylan N.V. : Geographical Revenue

Figure 29 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 30 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 31 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 Shire: Key Financials

Figure 36 Shire: Segmental Revenue

Figure 37 Shire: Geographical Revenue

Figure 38 Shionogi Inc.: Key Financials

Figure 39 Shionogi Inc.: Segmental Revenue

Figure 40 Shionogi Inc.: Geographical Revenue

Figure 41 Ligand Pharmaceuticals, Inc.: Key Financials

Figure 42 Ligand Pharmaceuticals, Inc.: Segmental Revenue

Figure 43 Ligand Pharmaceuticals, Inc.: Geographical Revenue